Skip to main content
. 2017 Jul;55:123–131. doi: 10.1016/j.neurobiolaging.2017.03.027

Table 1.

Discovery patient cohort

Group n Age (range) Gender (M:F)
sALS 27 64 (44–77) 15:12
Control 25 65 (49–77) 12:13
Noninflammatory neuropathy 7 65 (42–77) 5:2
Myopathy 7 66 (48–77) 3:4
Inflammatory neuropathy 8 59 (28–75) 5:3
Structural spinal disorders 6 57 (42–72) 4:3
Myasthenia gravis 8 68 (52–87) 4:3

Key: sALS, sporadic amyotrophic lateral sclerosis.

HHS Vulnerability Disclosure